Compare SCZM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCZM | CERS |
|---|---|---|
| Founded | N/A | 1991 |
| Country | Canada | United States |
| Employees | 455 | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.2M | 585.1M |
| IPO Year | N/A | 1996 |
| Metric | SCZM | CERS |
|---|---|---|
| Price | $8.42 | $2.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 395.4K | ★ 2.6M |
| Earning Date | 05-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $79.38 | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $5.61 | $1.15 |
| 52 Week High | $17.65 | $3.47 |
| Indicator | SCZM | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 34.29 |
| Support Level | $5.95 | $1.84 |
| Resistance Level | $8.40 | $2.84 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | 0.22 | -0.10 |
| Stochastic Oscillator | 93.42 | 22.22 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.